A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
NCT00661609
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
54
Enrollment
INDUSTRY
Sponsor class
Conditions
Bladder Cancer
Transitional Cell Bladder Cancer
Urethra Cancer
Ureter Cancer
Renal Pelvis Cancer
Interventions
DRUG:
AZD4877
Sponsor
AstraZeneca